Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001–2018

Leukemia volume 36, pages 275–278 (2022)Cite this article

Subjects

Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm characterized by excessive production of platelets—with occasionally elevated white blood cell counts—resulting in a heightened risk of thrombosis or hemorrhage [1]. Therefore, the main treatment goal is to prevent vascular events using platelet inhibition, cytoreductive therapy, or both [1].

There is an ongoing debate about whether ET patients have excess mortality than equivalent groups from the general population [2, 3]. The few available and outdated population-based studies show that ET patients diagnosed before 2000 have considerable excess mortality [4], whereas studies spanning earlier parts of the first decade of 2000 show lesser excess mortality [5, 6].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Primary treatment of patients with essential thrombocythemia in the Netherlands, 2001–2018.
Fig. 2: Relative survival of patients with essential thrombocythemia in the Netherlands, 2001–2018.

References

  1. Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135–44.

    Article  PubMed  Google Scholar 

  2. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol. 2005;130:153–65.

    Article  PubMed  Google Scholar 

  3. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–66.

    Article  PubMed  Google Scholar 

  4. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995. Am J Hematol. 1999;61:10–5. https://doi.org/10.1002/(SICI)1096-8652(199905)61:13.0.CO;2-I.

    Article  CAS  PubMed  Google Scholar 

  5. Hultcrantz M, Kristinsson SY, Andersson TM-L, Landgren O, Eloranta S, Derolf AR. et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C. et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302. https://doi.org/10.1182/blood-2002-04-1199.

    Article  CAS  PubMed  Google Scholar 

  8. Hultcrantz M, Ravn Landtblom A, Andréasson B, Samuelsson J, Dickman PW, Kristinsson SY, et al. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020;287:448–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–32.

    CAS  PubMed  Google Scholar 

  10. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.

    Article  CAS  PubMed  Google Scholar 

  11. Pérez Encinas MM, Sobas M, Gómez-Casares MT, Abuin Blanco A, Noya Pereira MS, Raya JM, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. Eur J Haematol. 2021;106:371–9.

    Article  PubMed  Google Scholar 

  12. Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood. 2021;137:2152–60.

    Article  CAS  PubMed  Google Scholar 

  13. Radkiewicz C, Johansson ALV, Dickman PW, Lambe M, Edgren G. Sex differences in cancer risk and survival: a Swedish cohort study. Eur J Cancer. 2017;84:130–40.

    Article  PubMed  Google Scholar 

  14. Dinnessen MAW, Visser O, Tonino SH, van der Poel MWM, Blijlevens NMA, Kersten MJ. et al. The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: a population-based study. eJHaem. 2020;1:489–97. https://doi.org/10.1002/jha2.108.

    Article  Google Scholar 

  15. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25.

    Article  PubMed  Google Scholar 

  16. Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124:184–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.

    Article  CAS  PubMed  Google Scholar 

  18. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organization (IKNL).

Author information

Authors and Affiliations

  1. Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands

    Tom S. M. Posthuma & Avinash G. Dinmohamed

  2. Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    Otto Visser

  3. Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands

    Peter A. W. te Boekhorst

  4. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    Avinash G. Dinmohamed

  5. Erasmus MC, University Medical Center Rotterdam, Department of Public Health, Rotterdam, The Netherlands

    Avinash G. Dinmohamed

  6. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands

    Avinash G. Dinmohamed

Authors
  1. Tom S. M. Posthuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter A. W. te Boekhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Avinash G. Dinmohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AGD designed the study; TSMP and AGD analyzed the data; OV was responsible for the data collection; TSMP wrote the paper with contributions from all authors, who also interpreted the data, and read, commented on, and approved the final version of the paper.

Corresponding author

Correspondence to Avinash G. Dinmohamed.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Posthuma, T.S.M., Visser, O., te Boekhorst, P.A.W. et al. Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001–2018. Leukemia 36, 275–278 (2022). https://doi.org/10.1038/s41375-021-01372-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-021-01372-5

This article is cited by

Search

Advanced search

Quick links